Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
Provided By GlobeNewswire
Last update: Oct 7, 2024
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks –
NASDAQ:KRON (6/16/2025, 8:00:02 PM)
0.8875
-0.01 (-0.57%)
Find more stocks in the Stock Screener
KRON Latest News and Analysis
11 days ago - ChartmillWhich stocks are gapping on Thursday?The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 days ago - ChartmillThese stocks are moving in today's pre-market sessionThe US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
